Explaining the limited utility of convalescent plasma from the first phase of the COVID-19 pandemic in treating those newly infected

The continued persistence of SARS-CoV-2 infections in predominantly unvaccinated individuals has meant a continued need for therapeutics to treat those hospitalized with COVID-19. Convalescent plasma containing SARS-CoV-2 neutralizing antibodies from recovered individuals is one therapy option but has been controversial. A new publication in Transfusion by CITF-funded researchers Drs. Steven Drews and Sheila O’Brien … Continue reading Explaining the limited utility of convalescent plasma from the first phase of the COVID-19 pandemic in treating those newly infected